457 related articles for article (PubMed ID: 29952768)
1. ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Vendetti FP; Karukonda P; Clump DA; Teo T; Lalonde R; Nugent K; Ballew M; Kiesel BF; Beumer JH; Sarkar SN; Conrads TP; O'Connor MJ; Ferris RL; Tran PT; Delgoffe GM; Bakkenist CJ
J Clin Invest; 2018 Aug; 128(9):3926-3940. PubMed ID: 29952768
[TBL] [Abstract][Full Text] [Related]
2. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
[TBL] [Abstract][Full Text] [Related]
3. The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Vendetti FP; Lau A; Schamus S; Conrads TP; O'Connor MJ; Bakkenist CJ
Oncotarget; 2015 Dec; 6(42):44289-305. PubMed ID: 26517239
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ; Min A; Im SA; Jang H; Lee KH; Lau A; Lee M; Kim S; Yang Y; Kim J; Kim TY; Oh DY; Brown J; O'Connor MJ; Bang YJ
Int J Cancer; 2017 Jan; 140(1):109-119. PubMed ID: 27501113
[TBL] [Abstract][Full Text] [Related]
5. WEE1 inhibitor and ataxia telangiectasia and RAD3-related inhibitor trigger stimulator of interferon gene-dependent immune response and enhance tumor treatment efficacy through programmed death-ligand 1 blockade.
Wu X; Kang X; Zhang X; Xie W; Su Y; Liu X; Guo L; Guo E; Li F; Hu D; Qin X; Fu Y; Peng W; Jia J; Wang C
Cancer Sci; 2021 Nov; 112(11):4444-4456. PubMed ID: 34382294
[TBL] [Abstract][Full Text] [Related]
6. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent.
Foote KM; Nissink JWM; McGuire T; Turner P; Guichard S; Yates JWT; Lau A; Blades K; Heathcote D; Odedra R; Wilkinson G; Wilson Z; Wood CM; Jewsbury PJ
J Med Chem; 2018 Nov; 61(22):9889-9907. PubMed ID: 30346772
[TBL] [Abstract][Full Text] [Related]
8. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy.
Dunne V; Ghita M; Small DM; Coffey CBM; Weldon S; Taggart CC; Osman SO; McGarry CK; Prise KM; Hanna GG; Butterworth KT
Radiother Oncol; 2017 Sep; 124(3):475-481. PubMed ID: 28697853
[TBL] [Abstract][Full Text] [Related]
10. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation.
Vendetti FP; Leibowitz BJ; Barnes J; Schamus S; Kiesel BF; Abberbock S; Conrads T; Clump DA; Cadogan E; O'Connor MJ; Yu J; Beumer JH; Bakkenist CJ
Sci Rep; 2017 Feb; 7():41892. PubMed ID: 28145510
[TBL] [Abstract][Full Text] [Related]
12. ATR kinase inhibitors NVP-BEZ235 and AZD6738 effectively penetrate the brain after systemic administration.
Fròsina G; Profumo A; Marubbi D; Marcello D; Ravetti JL; Daga A
Radiat Oncol; 2018 Apr; 13(1):76. PubMed ID: 29685176
[TBL] [Abstract][Full Text] [Related]
13. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
14. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
[TBL] [Abstract][Full Text] [Related]
15. ATR Inhibitor AZD6738 (Ceralasertib) Exerts Antitumor Activity as a Monotherapy and in Combination with Chemotherapy and the PARP Inhibitor Olaparib.
Wilson Z; Odedra R; Wallez Y; Wijnhoven PWG; Hughes AM; Gerrard J; Jones GN; Bargh-Dawson H; Brown E; Young LA; O'Connor MJ; Lau A
Cancer Res; 2022 Mar; 82(6):1140-1152. PubMed ID: 35078817
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
17. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
19. Effect of ATR Inhibition in RT Response of HPV-Negative and HPV-Positive Head and Neck Cancers.
Dok R; Glorieux M; Bamps M; Nuyts S
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33546122
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
Shima T; Shimoda M; Shigenobu T; Ohtsuka T; Nishimura T; Emoto K; Hayashi Y; Iwasaki T; Abe T; Asamura H; Kanai Y
Cancer Sci; 2020 Feb; 111(2):727-738. PubMed ID: 31821665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
